Castle Biosciences Inc
NASDAQ:CSTL
Intrinsic Value
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. [ Read More ]
The intrinsic value of one CSTL stock under the Base Case scenario is 33.405 USD. Compared to the current market price of 22.625 USD, Castle Biosciences Inc is Undervalued by 32%.
Valuation Backtest
Castle Biosciences Inc
Run backtest to discover the historical profit from buying and selling CSTL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Castle Biosciences Inc
Current Assets | 295.6m |
Cash & Short-Term Investments | 243.1m |
Receivables | 38.3m |
Other Current Assets | 14.2m |
Non-Current Assets | 157.7m |
PP&E | 37.7m |
Intangibles | 117.3m |
Other Non-Current Assets | 2.6m |
Current Liabilities | 47.7m |
Accounts Payable | 10.3m |
Accrued Liabilities | 33.9m |
Other Current Liabilities | 3.5m |
Non-Current Liabilities | 14.4m |
Long-Term Debt | 25k |
Other Non-Current Liabilities | 14.4m |
Earnings Waterfall
Castle Biosciences Inc
Revenue
|
219.8m
USD
|
Cost of Revenue
|
-45m
USD
|
Gross Profit
|
174.8m
USD
|
Operating Expenses
|
-242.8m
USD
|
Operating Income
|
-68m
USD
|
Other Expenses
|
10.5m
USD
|
Net Income
|
-57.5m
USD
|
Free Cash Flow Analysis
Castle Biosciences Inc
CSTL Profitability Score
Profitability Due Diligence
Castle Biosciences Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Castle Biosciences Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
CSTL Solvency Score
Solvency Due Diligence
Castle Biosciences Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Castle Biosciences Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CSTL Price Targets Summary
Castle Biosciences Inc
According to Wall Street analysts, the average 1-year price target for CSTL is 33.773 USD with a low forecast of 28.28 USD and a high forecast of 38.85 USD.
Ownership
CSTL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CSTL Price
Castle Biosciences Inc
Average Annual Return | 19.47% |
Standard Deviation of Annual Returns | 73.59% |
Max Drawdown | -88% |
Market Capitalization | 616.7m USD |
Shares Outstanding | 27 587 100 |
Percentage of Shares Shorted | 5.45% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.
Contact
IPO
Employees
Officers
The intrinsic value of one CSTL stock under the Base Case scenario is 33.405 USD.
Compared to the current market price of 22.625 USD, Castle Biosciences Inc is Undervalued by 32%.